Opinion 18 Jan 2023 Innovation in life sciences requires collaboration and community …proximity, coffee breaks and social events. It is natural to work next to an expert from another organisation, striking impromptu meetings and discussions which can lead almost anywhere. Open workspaces… January 18, 2023 - 5 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
In Depth 3 Nov 2022 What’s on the horizon for gene editing-based therapies? …Gene editing is a sizzling hot topic in the biotech industry, powered by advances in genetic tools such as CRISPR, TALENs and zinc-finger nucleases. Gene editing biotech players are developing… November 3, 2022 - 8 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 1 Jan 2023 Watch: Addressing IP with Starting Bloch …company also assists companies addressing fundraising, as well as helping with management and tech transfer. Patman gives companies a calendar of events to address issues as they arise. The platform… January 1, 2023 - 1 minutemin - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 1 Jul 2025 Is an HIV cure possible? The future of HIV therapy …same time, the U.S. government pulling back on HIV treatment efforts in Africa, now is a good time to take a look at the landscape. Table of contents HIV’s biotech… July 1, 2025 - 11 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Inside Labiotech 28 Oct 2016 Santé, Labiotech.eu is now 2 years old! (and what a journey so far) …for Biotech. Let’s see what we achieve in the next year! Thank you for all your support, it makes us all very proud and happy! See you around Labiotech.eu! The… October 28, 2016 - 5 minutesmins - By Philip Hemme Share WhatsApp Twitter Linkedin Email
News and Trends 3 May 2023 Positive study results: Lilly’s Alzheimer’s drug slows patients’ decline …of daily living such as managing finances, driving, engaging in hobbies, and conversing about current events. All secondary endpoints of cognitive and functional decline were also met and showed highly… May 3, 2023 - 8 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 17 Jan 2024 Bladder cancer treatment: where are we standing? …patients experienced grade ≥3 adverse events which refers to severe and significant medical events. In this case, the most common adverse event observed were ash maculo-papular, hyperglycemia, neutropenia, peripheral sensory… January 17, 2024 - 8 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
News and Trends 25 Sep 2019 Danish Smallpox Vaccine Gets FDA Approval to Fight Bioterrorism …in case the disease is released again. However, the traditional smallpox vaccine uses viral vectors that can replicate in the body. This risks adverse events such as necrosis and infection,… September 25, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
In Depth 9 May 2024 BTK inhibitors: can these drugs tackle cancer and autoimmunity? …condition. BTK inhibitors cause side effects However, while this class of drugs seems likely to treat MS in theory, many biotechs have struggled to get past clinical holds on their… May 9, 2024 - 7 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 17 Oct 2022 The challenges of translating CRISPR to the clinic …concerns, there are now a swathe of computational tools and assays available to assess and quantify these events. Indeed, in March this year the FDA released draft guidance on the… October 17, 2022 - 6 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 26 May 2023 Rocket Pharmaceuticals receives FDA designation for pyruvate kinase deficiency gene therapy …transfusion independence and improved quality of life with documented improvements via formal quality of life assessments. The safety profile appears favorable, with no RP-L301-related serious adverse events in either of… May 26, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 18 Nov 2019 Update: Single-Shot Vaccine for Chikungunya Lasts for a Year in Phase I …the focus of other biotechs too, including the Austrian biotech Themis, whose own vaccine for chikungunya recently had a successful phase II trial and is to begin phase III in… November 18, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email